Literature DB >> 31286557

Estimated kidney function in children and young adults with spina bifida: A retrospective cohort study.

David I Chu1,2, Lauren C Balmert3, Cameron M Arkin1, Theresa Meyer1, Ilina Rosoklija1, Belinda Li4, Kavita S Hodgkins5, Susan L Furth6,7, Earl Y Cheng1, Elizabeth B Yerkes1, Tamara Isakova8,9.   

Abstract

AIMS: Current estimated glomerular filtration rate (eGFR) equations may be inaccurate in patients with spina bifida (SB) because of reduced muscle mass and stature. Cross-sectional and longitudinal variability of eGFR were analyzed in these patients across multiple equations, hypothesizing greater variability in creatinine-based than cystatin-C (Cys-C)-based equations.
METHODS: This retrospective cohort study included children (age, 1-17.9 years) and adults (≥18 years) with SB from 2002-2017 at a large SB clinic. Those without all data needed to calculate eGFR were excluded. Four pediatric and three adult eGFR equations were compared for cross-sectional outcomes of eGFR and elevated office blood pressures using chronic kidney disease (CKD) stage classification, and for longitudinal outcome of eGFR slope over time using covariance pattern models accounting for repeated measures.
RESULTS: One hundred and eighty two children and 75 adults had greater than or equal to 1 set of data measurements; 118 and 52, respectively, had greater than or equal to 2 sets. The pediatric bedside Schwartz equation had the highest median eGFR and coefficient of variation. CKD stage classification by eGFR showed large differences across equations in children, with rates of eGFR < 60 and <90 ml/min/1.73 m2 ranging from 2%-9% and 5%-69%, respectively. Only one equation showed a significant inverse association between eGFR and blood pressure. Longitudinally, eGFR slopes over time were different across pediatric equations (P < .001) but not adult equations. The bedside Schwartz equation had a positive eGFR slope; the other Cys-C-containing equations had negative slopes.
CONCLUSIONS: Creatinine-based equations in children with SB vary considerably from cystatin-C-containing equations in calculating both single point-in-time eGFR values and eGFR trends over time.
© 2019 Wiley Periodicals, Inc.

Entities:  

Keywords:  chronic kidney disease; glomerular filtration rate; myelomeningocele; spina bifida

Year:  2019        PMID: 31286557      PMCID: PMC6706288          DOI: 10.1002/nau.24092

Source DB:  PubMed          Journal:  Neurourol Urodyn        ISSN: 0733-2467            Impact factor:   2.696


  23 in total

1.  The fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents.

Authors: 
Journal:  Pediatrics       Date:  2004-08       Impact factor: 7.124

2.  Prevalence of spina bifida among children and adolescents in 10 regions in the United States.

Authors:  Mikyong Shin; Lilah M Besser; Csaba Siffel; James E Kucik; Gary M Shaw; Chengxing Lu; Adolfo Correa
Journal:  Pediatrics       Date:  2010-07-12       Impact factor: 7.124

3.  Young adults with spina bifida may have higher occurrence of prehypertension and hypertension.

Authors:  Beth C Stepanczuk; Brad E Dicianno; Thomas S Webb
Journal:  Am J Phys Med Rehabil       Date:  2014-03       Impact factor: 2.159

4.  Neurocognitive functioning of children and adolescents with mild-to-moderate chronic kidney disease.

Authors:  Stephen R Hooper; Arlene C Gerson; Robert W Butler; Debbie S Gipson; Susan R Mendley; Marc B Lande; Shlomo Shinnar; Alicia Wentz; Matthew Matheson; Christopher Cox; Susan L Furth; Bradley A Warady
Journal:  Clin J Am Soc Nephrol       Date:  2011-07-07       Impact factor: 8.237

5.  Functional ambulation in patients with myelomeningocele.

Authors:  M M Hoffer; E Feiwell; R Perry; J Perry; C Bonnett
Journal:  J Bone Joint Surg Am       Date:  1973-01       Impact factor: 5.284

6.  Cystatin C as a marker of early renal insufficiency in children with congenital neuropathic bladder.

Authors:  Janelle A Fox; Anne G Dudley; Carlton Bates; Glenn M Cannon
Journal:  J Urol       Date:  2014-03-26       Impact factor: 7.450

7.  Fracture Burden and Risk Factors in Childhood CKD: Results from the CKiD Cohort Study.

Authors:  Michelle R Denburg; Juhi Kumar; Thomas Jemielita; Ellen R Brooks; Amy Skversky; Anthony A Portale; Isidro B Salusky; Bradley A Warady; Susan L Furth; Mary B Leonard
Journal:  J Am Soc Nephrol       Date:  2015-07-02       Impact factor: 10.121

8.  Estimating glomerular filtration rate from serum creatinine and cystatin C.

Authors:  Lesley A Inker; Christopher H Schmid; Hocine Tighiouart; John H Eckfeldt; Harold I Feldman; Tom Greene; John W Kusek; Jane Manzi; Frederick Van Lente; Yaping Lucy Zhang; Josef Coresh; Andrew S Levey
Journal:  N Engl J Med       Date:  2012-07-05       Impact factor: 91.245

9.  Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization.

Authors:  Alan S Go; Glenn M Chertow; Dongjie Fan; Charles E McCulloch; Chi-yuan Hsu
Journal:  N Engl J Med       Date:  2004-09-23       Impact factor: 91.245

Review 10.  Etiology and treatment of growth retardation in children with chronic kidney disease and end-stage renal disease: a historical perspective.

Authors:  Richard N Fine
Journal:  Pediatr Nephrol       Date:  2009-12-24       Impact factor: 3.714

View more
  9 in total

1.  Cystatin C as a biomarker of chronic kidney disease: latest developments.

Authors:  Stefanie W Benoit; Eileen A Ciccia; Prasad Devarajan
Journal:  Expert Rev Mol Diagn       Date:  2020-05-25       Impact factor: 5.225

2.  Kidney Function Surveillance in the National Spina Bifida Patient Registry: A Retrospective Cohort Study.

Authors:  David I Chu; Tiebin Liu; Priya Patel; Jonathan C Routh; Lijing Ouyang; Michelle A Baum; Earl Y Cheng; Elizabeth B Yerkes; Tamara Isakova
Journal:  J Urol       Date:  2020-03-06       Impact factor: 7.450

3.  Chronic kidney disease and upper tract concerns after congenital and acquired urinary tract abnormalities: considerations for transition of care in teens and young adults.

Authors:  Elizabeth B Yerkes; Michelle Baum; David I Chu
Journal:  World J Urol       Date:  2020-06-08       Impact factor: 4.226

Review 4.  Variation in Definitions of Kidney Abnormality in Patients with Spina Bifida: A Systematic Scoping Review.

Authors:  James T Rague; Jeremy D Lai; Peggy Murphy; Andrea Fawcett; Ryan Walton; Ilina Rosoklija; Diana K Bowen; Elizabeth B Yerkes; Earl Y Cheng; Kavita S Hodgkins; Jonathan C Routh; Tamara Isakova; David I Chu
Journal:  J Urol       Date:  2022-01-20       Impact factor: 7.600

5.  Augmentation cystoplasty in children with stages III and IV chronic kidney disease secondary to neurogenic bladder.

Authors:  Sanjay Sinha; Mehul Shah
Journal:  Asian J Urol       Date:  2021-06-01

6.  Diagnostic Test Characteristics of Ultrasound Based Hydronephrosis in Identifying Low Kidney Function in Young Patients with Spina Bifida: A Retrospective Cohort Study.

Authors:  David I Chu; Lauren C Balmert; Liqi Chen; Cameron Arkin; Theresa Meyer; Ilina Rosoklija; Diana K Bowen; Kavita S Hodgkins; Robin M Bowman; Earl Y Cheng; Elizabeth B Yerkes; Tamara Isakova
Journal:  J Urol       Date:  2020-11-18       Impact factor: 7.450

7.  Variability in Kidney Function Estimates in Emerging Adults With Spina Bifida: Implications for Transitioning From Pediatric to Adult Care.

Authors:  Diana K Bowen; Lauren C Balmert; Theresa Meyer; Ilina Rosoklija; Kavita S Hodgkins; Cybele Ghossein; Earl Y Cheng; Elizabeth B Yerkes; Tamara Isakova; David I Chu
Journal:  Urology       Date:  2020-11-24       Impact factor: 2.649

8.  Are Tubular Injury Markers NGAL and KIM-1 Useful in Pediatric Neurogenic Bladder?

Authors:  Joanna Bagińska; Agata Korzeniecka-Kozerska
Journal:  J Clin Med       Date:  2021-05-27       Impact factor: 4.241

9.  Trends in Procedures to Initiate Renal Replacement Therapy among People Living with Spina Bifida.

Authors:  Courtney S Streur; Nicholas M Moloci; Kate H Kraft; Aruna V Sarma; Vahakn B Shahinian; John M Hollingsworth
Journal:  J Urol       Date:  2020-07-27       Impact factor: 7.450

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.